Citizens Cuts CRISPR Therapeutics Price Target to $80, Keeps Market Outperform Rating
Citizens lowered its price objective for CRISPR Therapeutics (NASDAQ:CRSP) to $80.00 from $86.00 while maintaining a Market Outperform rating. The revised target implies roughly 50% upside from the stock's current quote of $53.35. The firm shifted valuation weight toward the company's in-vivo assets and reduced the role of CAR-T opportunities in it…